Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Biophytis SA ( (FR:ALBPS) ) is now available.
Biophytis SA has entered into exclusive negotiations with a major Chinese pharmaceutical lab to license BIO101 for co-development and commercialization in China, targeting viral respiratory infections, sarcopenia, and obesity. This move aligns with Biophytis’ strategic goals and could significantly enhance its market presence in China, the world’s second-largest pharmaceutical market, potentially benefiting millions of patients.
More about Biophytis SA
Biophytis SA is a clinical-stage biotechnology company focused on developing treatments for age-related diseases, with its main drug candidate being BIO101. The company operates in the biotechnology industry, specializing in muscle, respiratory, and metabolic diseases. It is headquartered in Paris, France, with subsidiaries in Cambridge, Massachusetts, USA, and Brazil.
YTD Price Performance: -25.71%
Average Trading Volume: 3,160
Technical Sentiment Consensus Rating: Buy
Current Market Cap: €2.78M
Find detailed analytics on ALBPS stock on TipRanks’ Stock Analysis page.